Last reviewed · How we verify
Interferon Alfa and CCI-779
Interferon Alfa and CCI-779 is a Combination immunotherapy and mTOR inhibitor Small molecule drug developed by Pfizer. It is currently in Phase 3 development for Renal cell carcinoma, Other advanced malignancies (phase 3 investigation).
This combination uses interferon alfa to enhance immune activation while CCI-779 (temsirolimus) inhibits mTOR to suppress tumor cell proliferation and promote apoptosis.
This combination uses interferon alfa to enhance immune activation while CCI-779 (temsirolimus) inhibits mTOR to suppress tumor cell proliferation and promote apoptosis. Used for Renal cell carcinoma, Other advanced malignancies (phase 3 investigation).
At a glance
| Generic name | Interferon Alfa and CCI-779 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Combination immunotherapy and mTOR inhibitor |
| Target | Interferon alfa receptor; mTOR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Interferon alfa is a cytokine that activates natural killer cells and macrophages to enhance anti-tumor immunity. CCI-779 is an mTOR inhibitor that blocks protein synthesis and cell cycle progression in cancer cells. The combination aims to synergize immune activation with direct anti-proliferative effects against tumor cells.
Approved indications
- Renal cell carcinoma
- Other advanced malignancies (phase 3 investigation)
Common side effects
- Fatigue
- Fever
- Anemia
- Thrombocytopenia
- Elevated liver enzymes
- Hyperlipidemia
Key clinical trials
- Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (PHASE3)
- Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer (PHASE1)
- Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma (PHASE2)
- Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interferon Alfa and CCI-779 CI brief — competitive landscape report
- Interferon Alfa and CCI-779 updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Interferon Alfa and CCI-779
What is Interferon Alfa and CCI-779?
How does Interferon Alfa and CCI-779 work?
What is Interferon Alfa and CCI-779 used for?
Who makes Interferon Alfa and CCI-779?
What drug class is Interferon Alfa and CCI-779 in?
What development phase is Interferon Alfa and CCI-779 in?
What are the side effects of Interferon Alfa and CCI-779?
What does Interferon Alfa and CCI-779 target?
Related
- Drug class: All Combination immunotherapy and mTOR inhibitor drugs
- Target: All drugs targeting Interferon alfa receptor; mTOR
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Renal cell carcinoma
- Indication: Drugs for Other advanced malignancies (phase 3 investigation)
- Compare: Interferon Alfa and CCI-779 vs similar drugs
- Pricing: Interferon Alfa and CCI-779 cost, discount & access